{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:33:43Z","timestamp":1787924023875,"version":"build-2784847793"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000109","name":"Prostate Cancer Canada","doi-asserted-by":"publisher","award":["2014-01"],"award-info":[{"award-number":["2014-01"]}],"id":[{"id":"10.13039\/501100000109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.clgc.2022.01.003","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T02:16:35Z","timestamp":1642212995000},"page":"e217-e226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Combining CAPRA-S With Tumor IDC\/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients"],"prefix":"10.1016","volume":"20","author":[{"given":"Renu","family":"Jeyapala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Olkhov-Mitsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Zlotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5004-0364","authenticated-orcid":false,"given":"Tapio","family":"Visakorpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8640-5786","authenticated-orcid":false,"given":"Theodorus","family":"van der Kwast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7684-1338","authenticated-orcid":false,"given":"Bharati","family":"Bapat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.01.003_bib0001","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4103\/1008-682X.178852","article-title":"Clinical variability and molecular heterogeneity in prostate cancer","volume":"18","author":"Shoag","year":"2016","journal-title":"Asian J Androl"},{"key":"10.1016\/j.clgc.2022.01.003_bib0002","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2022.01.003_bib0003","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/ng.3315","article-title":"Spatial genomic heterogeneity within localized, multifocal prostate cancer","volume":"47","author":"Boutros","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.clgc.2022.01.003_bib0004","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0005","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.eururo.2017.04.034","article-title":"A prostate cancer \"nimbosus\": genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies","volume":"72","author":"Chua","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0006","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1186\/s12885-017-3976-z","article-title":"Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations","volume":"18","author":"Bottcher","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2022.01.003_bib0007","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.ejca.2014.03.009","article-title":"Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort","volume":"50","author":"Trudel","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2022.01.003_bib0008","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/modpathol.2016.49","article-title":"Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy","volume":"29","author":"Kweldam","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0009","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-319-42740-9_6","article-title":"Intraductal carcinoma of prostate (IDC-P): From obscure to significant","volume":"28","author":"Chen","year":"2016","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.clgc.2022.01.003_bib0010","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.clgc.2022.01.003_bib0011","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: a validated alternative to the gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0012","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1002\/cncr.23908","article-title":"An updated catalog of prostate cancer predictive tools","volume":"113","author":"Shariat","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.01.003_bib0013","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1002\/cncr.26169","article-title":"The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy","volume":"117","author":"Cooperberg","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.01.003_bib0014","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.eururo.2014.05.039","article-title":"Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort","volume":"67","author":"Cooperberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0015","doi-asserted-by":"crossref","first-page":"D152","DOI":"10.1093\/nar\/gkq1027","article-title":"miRBase: integrating microRNA annotation and deep-sequencing data","volume":"39","author":"Kozomara","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clgc.2022.01.003_bib0016","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/978-3-642-55647-0_19","article-title":"Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the selenium and vitamin E cancer prevention trial","volume":"163","author":"Klein","year":"2003","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.clgc.2022.01.003_bib0017","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1200\/JCO.2012.47.1847","article-title":"DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer","volume":"31","author":"Haldrup","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0018","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djaa032","article-title":"Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN)","author":"Jamaspishvili","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2022.01.003_bib0019","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1464-410X.2010.09539.x","article-title":"A post-radical-prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis","volume":"107","author":"O'Brien","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2022.01.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1186\/1559-0275-10-13","article-title":"Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges","volume":"10","author":"Fuzery","year":"2013","journal-title":"Clin Proteomics"},{"key":"10.1016\/j.clgc.2022.01.003_bib0021","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0090-4295(02)02268-9","article-title":"Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. prostate-specific antigen","volume":"61","author":"Freedland","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2022.01.003_bib0022","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2022.01.003_bib0023","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","volume":"177","author":"Cookson","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0024","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/his.13891","article-title":"Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified delphi study","volume":"75","author":"Dufraing","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.clgc.2022.01.003_bib0025","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/PAS.0000000000000820","article-title":"Contemporary gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma","volume":"41","author":"Epstein","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0026","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.humpath.2007.03.014","article-title":"Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival","volume":"38","author":"Daneshmand","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0027","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.juro.2008.11.120","article-title":"DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy","volume":"181","author":"Weiss","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0028","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/14737159.2017.1302332","article-title":"Genomic tests to guide prostate cancer management following diagnosis","volume":"17","author":"Colicchia","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.clgc.2022.01.003_bib0029","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/1878-0261.12348","article-title":"Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer","volume":"12","author":"Murphy","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0030","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.2217\/fon-2016-0178","article-title":"Risk stratification of prostate cancer: Integrating multiparametric MRI, nomograms and biomarkers","volume":"12","author":"Watson","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0031","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/645030","article-title":"Contemporary radical prostatectomy","volume":"2011","author":"Fu","year":"2011","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.clgc.2022.01.003_bib0032","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/PAP.0b013e31825c6c0e","article-title":"Atypical cribriform lesions of the prostate: clinical significance, differential diagnosis and current concept of intraductal carcinoma of the prostate","volume":"19","author":"Shah","year":"2012","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0033","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2014.10.036","article-title":"A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy","volume":"67","author":"Klein","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0034","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3727\/096504017X14944585873631","article-title":"Long noncoding RNA SChLAP1 accelerates the proliferation and metastasis of prostate cancer via targeting miR-198 and promoting the MAPK1 pathway","volume":"26","author":"Li","year":"2018","journal-title":"Oncol Res"},{"key":"10.1016\/j.clgc.2022.01.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1186\/s13000-016-0478-2","article-title":"Grading of prostatic adenocarcinoma: current state and prognostic implications","volume":"11","author":"Gordetsky","year":"2016","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0036","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/modpathol.3800702","article-title":"Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance","volume":"19","author":"Guo","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clgc.2022.01.003_bib0037","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14789450.2019.1559062","article-title":"Cancer biomarker discovery and translation: proteomics and beyond","volume":"16","author":"Hristova","year":"2019","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.clgc.2022.01.003_bib0038","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/prca.200780174","article-title":"The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline","volume":"2","author":"Paulovich","year":"2008","journal-title":"Proteomics Clin Appl"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:39:54Z","timestamp":1778618394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1558767322000039"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.01.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining CAPRA-S With Tumor IDC\/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}